AI assistant
Sending…
Onxeo — Board/Management Information 2025
Mar 19, 2025
1573_iss_2025-03-19_c3704d3d-7733-47e9-b314-78c38d9a58b0.pdf
Board/Management Information
Open in viewerOpens in your device viewer
VALERIO THERAPEUTICS
Société anonyme à conseil d'administration au capital social de 21.610.998,20 euros Siège social : 49 boulevard du Général Martial Valin, 75015 Paris 410 910 095 R.C.S. Paris
LIST OF THE BOARD MEMBERS
POSITIONS HELD IN OTHER COMPANIES
As of March 19, 2025
| Name of Director | Other offices and functions |
|---|---|
| Julien MIARA Chief Executive Officer and Director |
• Managing Director at Invus • Director of Sensorion • Director of Versity |
| Jacques MALLET Director and Chairman of the Board |
• Chairman of Gamma-X Corporate Advisory • Director of Technoflex • Director of the Fournier Majoie Foundation |
| FINANCIERE DE LA MONTAGNE, represented by Nicolas TREBOUTA Director |
• Manager of SARL Financière de la Montagne • Manager of SCI Fleurus Immobilier • Chairman of SAS Dragon 8 • Managing partner of SC Financière des Associés • Chairman of the Supervisory Board of SCA Chevrillon & Associés • Manager of EARL Ferme de Bissy • Managing partner of SC Valois • Co-manager of SC Aster • Managing partner of SCI du Chardonnet |
| Bryan GIRAUDO Director |
• Chief Operating Officer and Chief Financial Officer of Gossamer Bio Inc • Director of Protagonist Therapeutics • Senior Managing Director at Leerink Partners |
| Antoine BAROUKY Chief Operating Officer and Director |
• Chairman & CEO of MAAsiRNA • Chairman & CEO of AB Global Strategy • Venture Partner at Invus |
| Shefali AGARWAL Director |
• Member of the Board of Directors of ITB Med (unlisted) • Member of the Board of Directors of Gritstone Bio (Nasdaq: GTRS) • Member of the Board of Directors of Fate Therapeutics (Nasdaq: FATE) |
More from Onxeo
Regulatory Filings
2026
May 18
Regulatory Filings
2026
May 18
Regulatory Filings
2026
May 4
Regulatory Filings
2026
May 4
Earnings Release
2026
Apr 29
Earnings Release
2026
Apr 29
Board/Management Information
2025
Dec 17
Board/Management Information
2025
Dec 17
Interim / Quarterly Report
2025
Oct 30
Interim / Quarterly Report
2025
Oct 30